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Abstract
Introduction Hypertrophic cardiomyopathy (HCM) is an au-
tosomal dominant heart disease mostly due to mutations in
genes encoding sarcomeric proteins. HCM is characterised by
asymmetric hypertrophy of the left ventricle (LV) in the ab-
sence of another cardiac or systemic disease. At present it
lacks specific treatment to prevent or reverse cardiac dysfunc-
tion and hypertrophy in mutation carriers and HCM patients.
Previous studies have indicated that sarcomere mutations
increase energetic costs of cardiac contraction and cause myo-
cardial dysfunction and hypertrophy. By using a translational
approach, we aim to determine to what extent disturbances of
myocardial energymetabolism underlie disease progression in
HCM.
Methods Hypertrophic obstructive cardiomyopathy (HOCM)
patients and aortic valve stenosis (AVS) patients will undergo
a positron emission tomography (PET) with acetate and car-
diovascular magnetic resonance imaging (CMR) with tissue
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tagging before and 4 months after myectomy surgery or aortic
valve replacement + septal biopsy. Myectomy tissue or septal
biopsy will be used to determine efficiency of sarcomere con-
traction in-vitro, and results will be compared with in-vivo
cardiac performance. Healthy subjects and non-hypertrophic
HCM mutation carriers will serve as a control group.
Endpoints Our study will reveal whether perturbations in
cardiac energetics deteriorate during disease progression in
HCM and whether these changes are attributed to cardiac
remodelling or the presence of a sarcomere mutation per se.
In-vitro studies in hypertrophied cardiac muscle from HOCM
and AVS patients will establish whether sarcomere mutations
increase ATP consumption of sarcomeres in human myocar-
dium. Our follow-up imaging study in HOCM and AVS
patients will reveal whether impaired cardiac energetics are
restored by cardiac surgery.
Keywords Hypertrophic cardiomyopathy . Carrier .
Myocardial energetics . Sarcomere mutations
Introduction
Hypertrophic cardiomyopathy (HCM) is a common genetic
cardiac disease with an estimated prevalence of 1:500 in
the general population. HCM is most frequently caused by
mutations in genes encoding sarcomeric proteins and is
characterised by asymmetric remodelling of the left ven-
tricle (LV) in the absence of increased loading conditions
or (infiltrative) systemic disease likely to cause hypertro-
phy [1]. The phenotypic expression has intrafamilial and
interfamilial variability, ranging from no or mild symptoms
throughout life to the occurrence of progressive heart fail-
ure or sudden cardiac death at young age. Apart from
surgical removal of septal myocardium in patients with
symptomatic left ventricular outflow tract obstruction, no
treatment to prevent or reverse cardiac dysfunction and
development of hypertrophy exists, as the exact mecha-
nisms by which mutations cause LV dysfunction and hy-
pertrophy are still incompletely resolved.
Sarcomere contractility
Initially, it was proposed that sarcomere genemutations would
depress myocardial contractility leading to compensatory hy-
pertrophy by activation of neuroendocrine and mechanical
responses [2]. Low force generating capacity by sarcomeres
has been found in single cardiomyocytes isolated from pa-
tients with obstructive HCM (HOCM) [3–7]. The low cardio-
myocyte force development in HCM patients was largely
explained by hypertrophy and reduced myofibrillar density
in HCM with mutations in genes encoding cardiac myosin-
binding protein-C and thin filament proteins [7]. In addition,
some specific missense mutations, in particular in the gene
encoding the thick filament protein myosin heavy chain, lower
the intrinsic force generating capacity of sarcomeres, possibly
by changing cross-bridge turnover kinetics [7, 8]. Opposite to
low maximal force generating capacity, both in-vitro and in-
vivo studies using various recombinant proteins and transgen-
ic mice models observed increased Ca2+ sensitivity of the
myofilaments indicative for a mutation-induced increase in
contractility at submaximal Ca2+ concentrations [9, 10]. Our
recent studies in samples from HOCM patients indicated that
high myofilament Ca2+ sensitivity is indeed a common char-
acteristic of human HCM, though can be partly explained by
altered phosphorylation of sarcomeres rather than the muta-
tion itself [5, 7, 11]. In addition, missense mutations perturb
length-dependent activation of sarcomeres evident from a
blunted increase in force development upon an increase in
sarcomere length [11]. Overall, the effect of an HCMmutation
on contractile performance of the sarcomeres is determined by
which sarcomeric gene is affected, the location of the mutation
within the gene (and protein) and dose of the mutant protein
ultimately resulting from the genetic mutation.
Energetics of cardiac contraction
Apart from perturbed contractility, cardiac performance may
be impaired by altered energetics of the myocardium. The
energy homeostasis may be affected by the HCM mutation
through the following mechanism: both impaired and in-
creased contractility (at physiological Ca2+ concentrations)
may lead to increased ATP utilisation of the sarcomeres and
a relative depletion of energy storage. A mismatch between
energy supply and demand is thought to initiate a self-
perpetuating cycle in which other ATP consuming mecha-
nisms in cardiomyocytes, such as re-uptake of Ca2+ by the
sarcoplasmic reticulum Ca2+ ATPase pump, will prolong cy-
tosolic Ca2+ transients and stimulate Ca2+ dependent hyper-
trophic signalling pathways [12], rendering the myocardium
less efficient in patients with HCM mutations. Indeed, several
studies in transgenic mice harbouring mutations in genes
encoding myosin heavy chain [13] and the thin filament
protein troponin T [14, 15] suggested increased ATP
utilisation by the sarcomeres. In humans, indirect evidence
of increased ATP consumption has been obtained using car-
diac imaging studies. With magnetic resonance spectroscopy,
it has been shown that cardiac phosphocreatine (PCr) to ATP
ratio, an indirect measure of energy status, is reduced by 30 %
in HCM patients compared with controls, irrespective of the
extent of hypertrophy [16, 17]. This suggests that energy
deficiency is a primary event rather than a secondary conse-
quence of left ventricular remodelling. This is supported
by results from a pharmacological intervention study in
HCM patients using perhexiline, a modulator of substrate
metabolism, shifting metabolism from free fatty acids to the
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more efficient glucose. After 4.6±1.8 months of perhexiline
treatment, improved diastolic function and increased exercise
capacity were observed in HCM patients treated with
perhexiline [18]. However, the positive effects of perhexiline
may also be explained by improvement of myocardial perfu-
sion. Moreover, direct evidence of increased ATP utilisation
for sarcomere contraction in human HCM is lacking. There-
fore, the assumption that increased ATP consumption of af-
fected sarcomeres plays an important role in the development
of HCM is still debatable. By using a translational approach,
within the ENGINE study (ENerGetIcs in hypertrophic car-
diomyopathy: traNslation between MRI, PET and cardiac
myofilament function), we aim to determine to what extent
disturbances of myocardial energy metabolism underlie dis-
ease progression in HCM.
Materials & methods
Study population
To investigate whether changes in myocardial energy metab-
olism depend on the presence of a sarcomere mutation and/or
are explained by hypertrophic remodelling of the heart, a
comparison is made between four groups. Firstly, HCM mu-
tation carriers without evident LV hypertrophy are compared
with manifest HCM patients with LVoutflow tract obstruction
(HOCM) to assess the progress of changes in cardiac energet-
ics during HCM disease development. These groups are com-
pared with a healthy control group and patients with acquired
LV remodelling due to aortic valve stenosis (AVS). The latter
group will reveal to what extent LV remodelling underlies
changes in cardiac energetics.
Exclusion criteria includes (previously documented)
coronary artery disease; previous septal reduction therapy;
poor left ventricular function (ejection fraction <50 %); a
history of diabetes mellitus or hypertension (defined as a
blood pressure ≥140/90 mmHg); contraindications to mag-
netic resonance imaging, including pacemaker and defi-
brillator implantation; severe claustrophobia and signifi-
cant renal dysfunction (estimated glomerular filtration rate
(eGFR) <30 ml/min/1.73 m2).
The Medical Ethics Review Committee of the participating
hospitals (VU University Medical Center (VUmc) in Amster-
dam; Onze Lieve Vrouwe Gasthuis (OLVG) in Amsterdam;
St. Antonius Hospital (AZN) in Nieuwegein and University
Medical Center (UMCU) in Utrecht) approved the study.
Informed consent will be obtained from all participants.
Study design
HOCM patients (maximum LV wall thickness ≥13 mm in the
absence of other cardiac or systemic causes of LV hypertrophy)
and AVS patients will undergo a transthoracic echocardiogra-
phy (TTE), positron emission tomography (PET) with acetate,
cardiovascular magnetic resonance imaging (CMR)with tissue
tagging and a cardiopulmonary exercise test (CPET) before
and 4 months after myectomy surgery or aortic valve replace-
ment (Fig. 1). In-vitro measurements of sarcomere ATP con-
sumption for force development will be performed in cardiac
samples from HOCM patients obtained during surgical
myectomy and fromAVS patients with concentric hypertrophy
during valve replacement (peak transvalvular gradient
of >50 mmHg, no more than minimal aortic regurgitation
(grade ≤1). In-vitro results will be correlated with in-vivo
cardiac performance. The healthy control group and non-
hypertrophic carriers with normal LV geometry will only un-
dergo baseline in-vivo measurements.
Transthoracic echocardiography
Echocardiography will be performed according to the Amer-
ican Society of Echocardiography guidelines. LV dimensions
will be measured at end diastole by 2D guided M-mode
echocardiography. Continuous wave Doppler will be used to
derive LVoutflow tract gradient and peak transvalvular pres-
sure gradient across the aortic valve. To assess diastolic LV
function, pulsed-wave Doppler transmitral inflow will be
obtained from the apical 4-chamber view.
Positron emission tomography
Before PET acquisition, venous blood will be drawn and
metabolic parameters such as NH2-terminal pro-brain natri-
uretic peptide (NT-proBNP), haemoglobin (Hb), creatinine,
free fatty acids (FFA), glucose, and lactate levels will be
determined. Subsequently, patients will undergo a [11C]-ace-
tate PET study to quantitatively evaluate regional oxygen
consumption according to the 17-segment model of the Amer-
ican Heart Association [19] (Fig. 2a).
Cardiovascular magnetic resonance imaging
LV volume analysis will be performed by manually drawing
epicardial and endocardial contours on all end-diastolic (ED)
and end-systolic (ES) LV short-axis cine images (Fig. 2b).
Global LV function parameters will be determined: LVED
volume (LVEDV), LVES volume (LVESV), LVejection frac-
tion (LVEF), and LV myocardial mass. CMR tissue tagging
images will be used to quantify regional intramyocardial
deformation, allowing to measure segmental peak systolic
circumferential strain and diastolic circumferential strain rate.
Finally, each myocardial segment will be evaluated for the
presence of late gadolinium enhancement (LGE). The combi-
nation of CMR and PET imaging will allow detailed, non-
invasive measurement of myocardial efficiency [20].
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Cardiopulmonary exercise test
Cyclo-ergometry exercise will be performed using a ramp
protocol of 10–20 watts per min. Individuals will cycle until
they reach the point of exhaustion or symptom limitation.
Breath-by-breath gas exchange analysis will be performed.
Respiratory gases will be sampled continuously via a mouth-
piece and analysed for oxygen and an infrared sensor for
carbon dioxide. Using this method, peak oxygen consumption
(peak VO2), defined as the highest VO2 achieved during
exercise, can be determined before and after surgery.
In-vitro measurements
ATP consumption, i.e. ATPase activity, will be measured
using an enzyme-coupled assay in membrane-permeabilised
multicellular muscle strips as described previously [21]. The
economy of muscle contraction is expressed as tension cost
Fig. 1 ENGINE study design:
translational, prospective,





AVR, aortic valve replacement
Fig. 2 The measurement of segmental myocardial efficiency. a . 17-
segment model according to the consensus of the American Heart Asso-
ciation. Left ventricular short-axis slices with location of the slices and the
names of the segments. AN=anterior, AS=anteroseptum, IS=
inferoseptum, IN=inferior, IL=inferolateral, AL=anterolateral, S=septal,
L=lateral . b . Left ventricular short-axis cine images in 1. end-diastolic
(ED) and 2. end-systolic (ES) phase. 3. CMR tissue tagging image with
vertical taglines and 4. Parametric image of [11C]-acetate washout as
obtained after kinetic analysis
570 Neth Heart J (2013) 21:567–571
(TC), i.e. the amount of ATP used during the development of
maximum force (ATPase activity/Tension generation).
Study endpoints
Our study will reveal whether perturbations in cardiac ener-
getics deteriorate during disease progression in HCM and
whether these changes are attributed to cardiac remodelling
or the presence of a sarcomere mutation per se. In vitro studies
in hypertrophied cardiac muscle from HOCM and AVS pa-
tients will establish whether sarcomere mutations increase
ATP consumption of sarcomeres in human myocardium.
Our follow-up imaging study in HOCM and AVS patients
will reveal whether impaired cardiac energetics are restored by
cardiac surgery.
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